Intestinal barrier function enhancement

Intestinal barrier function enhancement refers to the physiological process of strengthening the mucosal and epithelial layers of the gastrointestinal tract to prevent the translocation of pathogens, toxins, and antigens into the systemic circulation (PMID: 22503431). This barrier is primarily maintained by a complex network of tight junction proteins, such as claudins, occludin, and zonula occludens-1 (ZO-1), alongside a protective mucus layer and specialized immune cells (StatPearls: Physiology, Gastrointestinal Barrier). Dysfunction in this barrier, often referred to as increased intestinal permeability or leaky gut, is a hallmark of several inflammatory and autoimmune conditions, including Crohn's disease, ulcerative colitis, and Celiac disease (PMID: 28123927). Therapeutic strategies to enhance this function include the use of tight junction modulators like Larazotide acetate, which prevents junctional disassembly, and growth factors like Teduglutide (a GLP-2 analog) that promote mucosal repair and surface area expansion (PMID: 26153773). While improving barrier integrity is a critical clinical objective, it is classified as a complex physiological outcome or therapeutic effect rather than a single molecular target.

Other names

Gut barrier integrity maintenanceIntestinal permeability regulationMucosal barrier reinforcementTight junction modulation

Enhancement is achieved through the stabilization of tight junction complexes (claudins, occludin, ZO-1), stimulation of goblet cell mucus secretion, and promotion of enterocyte proliferation and survival (PMID: 22503431, PMID: 26153773).